Island Pharmaceuticals Administers Second Cohort in ISLA-101 Single Ascending Dose Study

Written By Kathleen Otto

Island Pharmaceuticals Ltd achieves a significant milestone by successfully dosing all eight subjects in the second cohort of its ISLA-101 Single Ascending Dose (SAD) study. ISLA-101, a promising drug candidate repurposed for preventing and treating dengue and other mosquito-borne diseases, is undergoing escalating dose administration to verify safe and effective blood concentrations against the dengue virus in healthy subjects.

Kathleen Otto
Previous

Xponential Fitness and American Cancer Society Partner to Fight Cancer through Health and Wellness
Next

FormBio Receives Nomination for The Medicine Maker's 2023 Innovation Awards